Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia

A. M. Martelli, M. Nyåkern, G. Tabellini, R. Bortul, P. L. Tazzari, C. Evangelisti, L. Cocco

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias. Hence, this pathway is an attractive target for the development of novel anticancer strategies. Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells. Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations. Small molecules designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro. Thus, inhibitory molecules are currently being developed for clinical use either as single agents or in combination with conventional therapies. However, the PI3K/Akt pathway is important for many physiological cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects. In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacological inhibitors.

Original languageEnglish
Pages (from-to)911-928
Number of pages18
JournalLeukemia
Volume20
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

1-Phosphatidylinositol 4-Kinase
Acute Myeloid Leukemia
Signal Transduction
Apoptosis
Myeloid Cells
Drug Resistance
Cell Survival
Up-Regulation
Pharmacology
Insulin
Mutation
Survival
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • 3-phosphorylated inositol lipids
  • Apoptosis
  • Drug resistance
  • Signal transduction networks
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Martelli, A. M., Nyåkern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., & Cocco, L. (2006). Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia, 20(6), 911-928. https://doi.org/10.1038/sj.leu.2404245

Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. / Martelli, A. M.; Nyåkern, M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Evangelisti, C.; Cocco, L.

In: Leukemia, Vol. 20, No. 6, 06.2006, p. 911-928.

Research output: Contribution to journalArticle

Martelli, AM, Nyåkern, M, Tabellini, G, Bortul, R, Tazzari, PL, Evangelisti, C & Cocco, L 2006, 'Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia', Leukemia, vol. 20, no. 6, pp. 911-928. https://doi.org/10.1038/sj.leu.2404245
Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006 Jun;20(6):911-928. https://doi.org/10.1038/sj.leu.2404245
Martelli, A. M. ; Nyåkern, M. ; Tabellini, G. ; Bortul, R. ; Tazzari, P. L. ; Evangelisti, C. ; Cocco, L. / Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. In: Leukemia. 2006 ; Vol. 20, No. 6. pp. 911-928.
@article{f14610d3278d4721931f6afbd73038bf,
title = "Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia",
abstract = "The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias. Hence, this pathway is an attractive target for the development of novel anticancer strategies. Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells. Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations. Small molecules designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro. Thus, inhibitory molecules are currently being developed for clinical use either as single agents or in combination with conventional therapies. However, the PI3K/Akt pathway is important for many physiological cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects. In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacological inhibitors.",
keywords = "3-phosphorylated inositol lipids, Apoptosis, Drug resistance, Signal transduction networks, Targeted molecular therapy",
author = "Martelli, {A. M.} and M. Ny{\aa}kern and G. Tabellini and R. Bortul and Tazzari, {P. L.} and C. Evangelisti and L. Cocco",
year = "2006",
month = "6",
doi = "10.1038/sj.leu.2404245",
language = "English",
volume = "20",
pages = "911--928",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Phosphoinositide 3-kinase/ Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia

AU - Martelli, A. M.

AU - Nyåkern, M.

AU - Tabellini, G.

AU - Bortul, R.

AU - Tazzari, P. L.

AU - Evangelisti, C.

AU - Cocco, L.

PY - 2006/6

Y1 - 2006/6

N2 - The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias. Hence, this pathway is an attractive target for the development of novel anticancer strategies. Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells. Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations. Small molecules designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro. Thus, inhibitory molecules are currently being developed for clinical use either as single agents or in combination with conventional therapies. However, the PI3K/Akt pathway is important for many physiological cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects. In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacological inhibitors.

AB - The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is crucial to many aspects of cell growth, survival and apoptosis, and its constitutive activation has been implicated in the both the pathogenesis and the progression of a wide variety of neoplasias. Hence, this pathway is an attractive target for the development of novel anticancer strategies. Recent studies showed that PI3K/Akt signaling is frequently activated in acute myeloid leukemia (AML) patient blasts and strongly contributes to proliferation, survival and drug resistance of these cells. Upregulation of the PI3K/Akt network in AML may be due to several reasons, including FLT3, Ras or c-Kit mutations. Small molecules designed to selectively target key components of this signal transduction cascade induce apoptosis and/or markedly increase conventional drug sensitivity of AML blasts in vitro. Thus, inhibitory molecules are currently being developed for clinical use either as single agents or in combination with conventional therapies. However, the PI3K/Akt pathway is important for many physiological cellular functions and, in particular, for insulin signaling, so that its blockade in vivo might cause severe systemic side effects. In this review, we summarize the existing knowledge about PI3K/Akt signaling in AML cells and we examine the rationale for targeting this fundamental signal transduction network by means of selective pharmacological inhibitors.

KW - 3-phosphorylated inositol lipids

KW - Apoptosis

KW - Drug resistance

KW - Signal transduction networks

KW - Targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=33744457653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744457653&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404245

DO - 10.1038/sj.leu.2404245

M3 - Article

C2 - 16642045

AN - SCOPUS:33744457653

VL - 20

SP - 911

EP - 928

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -